ClinicalTrials.gg
RecruitingNCT07486791Updated May 5, 2026

A Clinical Study on the Effect of Cardiopulmonary Function and Quality of Life in Patients With Acute Coronary Syndrome Complicated by Heart Failure by "Lying-Sitting-Standing" Sequential Baduanjin

An interventional study of standard treatment and routine rehabilitation nursing guidance and "Lying-Sitting-Standing" Sequential Baduanjin in ACS (Acute Coronary Syndrome) and HF - Heart Failure, sponsored by Xiling Qi. Recruiting at 1 site in China. Open to participants aged Up to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Xiling Qi · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
Up to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 185 studies in Acute Coronary Syndrome with a site in China — 55 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.

Planned enrollment
104th of 115
65 · median 499
Started
2026
with 9 others
No phase
47 of 185
20 open now
Primary completion
2027-03
later than 41 of 62 live
Registered
179th of 185
by date

Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 104th largest by planned enrollment of the 115 interventional ones that give a count, is one of 10 that started in 2026, is one of 47 with no phase, reaches primary completion later than 41 of the 62 other live ones, and was the 179th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

55 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:

49 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: Up to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Acute Coronary Syndrome with a site in China, or all of them as a file.
02

Study summary

This study investigates the effects of a sequential "lying-sitting-standing" Baduanjin intervention on patients with acute coronary syndrome complicated by heart failure. By evaluating cardiopulmonary function and quality of life through indicators such as echocardiography, NT-proBNP, 6MWT, NYHA classification, and SF-36, we aim to compare its efficacy with conventional treatment. The objective is to provide new insights for early cardiac rehabilitation strategies in patients with acute coronary syndrome complicated by heart failure

03

Conditions studied

  • ACS (Acute Coronary Syndrome)
  • HF - Heart Failure
04

Who can participate

Ages eligible
Up to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients meeting the diagnostic criteria for ACS (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction)
  • Complicated by heart failure during hospitalization
  • Age ≤ 85 years
  • Muscle strength ≥ grade 3
  • No history of mental illness, conscious and able to cooperate independently with this study
  • Voluntarily participate in this study and sign the form

Exclusion criteria

Exclusion Criteria:

  • Patients with persistent heart failure symptoms or functional class IV despite optimal pharmacological therapy;
  • Patients with to cardiac rehabilitation, such as uncontrolled hypertension, uncontrolled arrhythmias, or hemodynamic instability;
  • Patients with untreated structural heart disease, such as heart failure caused by valvular heart disease or congenital heart disease;
  • Patients in the acute phase of various diseases, such as severe infection, deep vein thrombosis, or severe hepatic or renal failure;
  • Patients with disabilities, bone or joint diseases, or neurological disorders that preclude participation in Baduanjin exercises;
  • Patients with a of less than one year;
  • Patients currently participating in other clinical trials.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
65 participants (estimated)

Study arms

  • Placebo comparator
    standard treatment and routine rehabilitation nursing guidance

    Behavioral: standard treatment and routine rehabilitation nursing guidance

  • Experimental
    "Lying-Sitting-Standing" Sequential Baduanjin

    Behavioral: "Lying-Sitting-Standing" Sequential Baduanjin

Interventions

  • Behavioralstandard treatment and routine rehabilitation nursing guidance

    standard treatment and routine rehabilitation nursing guidance

  • Behavioral"Lying-Sitting-Standing" Sequential Baduanjin

    "Lying-Sitting-Standing" Sequential Baduanjin

06

What researchers measure

Primary outcomes

  1. Patients were stratified based on their 6-minute walk test distance

    The 6-minute walk test is an objective indicator for evaluating exercise tolerance in patients with heart failure, representing the total distance a patient can walk in 6 minutes. The results are categorized into four grades based on the distance covered: \<300 m, 300-374.9 m, 375-449.9 m, and ≥450 m.

    Time frame: From enrollment to the end of the 12-week treatment

  2. NYHA(New York Heart Association)classification of cardiac function

    The New York Heart Association (NYHA) Functional Classification, proposed in 1928 and still in use today, categorizes patients into classes Ⅰ through Ⅳ, with class Ⅰ representing the best condition and class Ⅳ the worst.

    Time frame: From enrollment to the end of the 12-week treatment

  3. Left ventricular ejection fraction (LVEF) on echocardiography

    Ejection fraction is a ratio reflecting the efficiency of cardiac pumping, defined as the percentage of blood volume pumped out by the left ventricle during each contraction (stroke volume, SV) relative to its end-diastolic volume (EDV). It is measured using the Simpson's method on echocardiography.

    Time frame: From enrollment to the end of the 12-week treatment

  4. C-reactive protein levels

    Unit:mg/L

    Time frame: From enrollment to the end of the 12-week treatment

  5. SF-36(ShortForm36HealthSurvey)

    The SF-36 is a generic scale developed by the Boston Health Research Institute in the United States in 1988, based on the Medical Outcomes Study Short-Form (MOS SF) originally devised by Stewart et al. It is used to assess health-related quality of life in populations. The scale contains 36 items and comprehensively evaluates health-related quality of life across eight dimensions: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). Scores for each dimension are converted using specific formulas to a scale of 0 to 100, with higher scores indicating better health status.

    Time frame: From enrollment to the end of the 12-week treatment

  6. NT-proBNP(N-terminal pro-B-type natriuretic peptide)levels

    Unit:pg/ml

    Time frame: From enrollment to the end of the 12-week treatment

  7. FMD(flow-mediated vasodilation)

    Flow-mediated dilation (FMD) is a non-invasive method for assessing vascular endothelial function, based on the mechanism by which endothelial cells respond to changes in shear stress. It uses high-frequency ultrasound (7-12 MHz) to measure the inner diameter of the brachial artery at rest, record the peak blood flow velocity and changes in vessel diameter following reactive hyperemia, and calculate the maximum vasodilatory response. The calculation formula is: FMD = \[(post-reactive diameter - baseline diameter) / baseline diameter\] × 100%.

    Time frame: From enrollment to the end of the 12-week treatment

  8. ADL(Activities of Daily Living Scale)

    The ADL , which stands for the Activities of Daily Living Scale, was developed by Lawton and Brody in 1969. It is primarily used to assess an individual's ability to perform daily activities. The basic activities of daily living evaluated by this scale include ten items: feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, bed-to-chair transfer, walking on level ground, and stair climbing. The total score is 100 points. Based on the score, functional status is classified into four levels: ≤40 indicates severe dependence; 41-60 indicates moderate dependence; 61-99 indicates mild dependence; and 100 indicates independence.

    Time frame: From enrollment to the end of the 12-week treatment

07

Study locations

1 of 1 sites recruiting
  • Second Hospital of Shanxi Medical
    Taiyuan, Shanxi 030001, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 11 months is below that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 20, 2026
StartActual
Mar 10, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 1, 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07486791
Lead sponsor
Xiling Qi
Responsible party
Xiling Qi (assistant director physician, Second Hospital of Shanxi Medical University) — Sponsor-investigator
First posted
Mar 20, 2026
Start date
Mar 10, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion